Lack of natalizumab concentration increase before PML argues against extending dosing interval
…
MS Relapses During Natalizumab Therapy Traced to Drug’s Greater Impact on Regulatory T-cells
…
Stuart Schlossman
Tysabri’s Success in Impairing the Immune System in RRMS May Be Source of Its Problems
…
Stuart Schlossman
ClinicSpeak & NeuroSpeak: sequencing DMTs switching from natalizumab to alemtuzumab
…
Stuart Schlossman
ClinicSpeak: natalizumab or alemtuzumab?
…
Stuart Schlossman
NATALIZUMAB MISSES ENDPOINT IN SECONDARY PROGRESSIVE MS
…
Stuart Schlossman
Tysabri No Help in SPMS – Drug didn’t reduce disability progression but may benefit upper limb function
…
Stuart Schlossman
EMA advocates more regular MRIs for MS patients on Biogen’s mAb Tysabri
By Gareth MacDonald+, 17-Feb-2016 Multiple sclerosis patients taking Tysabri (natalizumab) who are deemed to be at high risk for the lethal…
Stuart Schlossman
MS Neurologist Argues for Continued Use of Natalizumab as Disease Treatment
In a recent study of more than 1,200 patients with multiple sclerosis (MS), a research team reported that treatment with the…
Stuart Schlossman
Study Shows That People with MS Taking Natalizumab Develop Antibodies to the JC Virus at Higher Than Normal Rates, Emphasizing Need for Regular Monitoring
January 27, 2016 A study by researchers in Germany and France observed changes in JC virus antibody status in two…
Stuart Schlossman
